/GMED
GMED Stock - Globus Medical, Inc.
Healthcare|Medical - DevicesNYSE
$87.06+0.21%
+$0.18 (+0.21%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.96
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).55
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+2.5%upside
Target: $89.24
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GMED
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$86.19 – $87.93
TARGET (TP)$89.25
STOP LOSS$80.10
RISK/REWARD1:0.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.07
52W High$94.93
52W Low$51.79
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.52B | $1.57B | $1.02B | $958.10M | $789.04M |
| Gross Profit | $1.48B | $1.02B | $759.12M | $718.88M | $571.58M |
| Gross Margin | 58.9% | 65.1% | 74.2% | 75.0% | 72.4% |
| Operating Income | $165.99M | $133.14M | $227.95M | $171.95M | $111.43M |
| Net Income | $102.98M | $122.87M | $190.17M | $149.19M | $102.28M |
| Net Margin | 4.1% | 7.8% | 18.6% | 15.6% | 13.0% |
| EPS | $0.76 | $1.09 | $1.89 | $1.48 | $1.04 |
Company Overview
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
47%
Hold / Neutral
8
47%
Sell / Underperform
1
6%
Analyst Consensus🔴 Bearish
8 Bullish9 Neutral/Bearish
Price Targets
$76
Average Target
↓ 12.5% Downside
Now
$60
Low
$76
Average
$100
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 7th 2025 | Truist | Upgrade | Buy | $93 |
| November 7th 2025 | BofA Securities | Upgrade | Buy | $91 |
| October 28th 2025 | Stifel | Resumed | Hold | $64 |
| May 27th 2025 | BTIG Research | Downgrade | Neutral | - |
| January 10th 2025 | BofA Securities | Upgrade | Neutral | $97 |
| December 2nd 2024 | Morgan Stanley | Upgrade | Overweight | $100← $83 |
| August 7th 2024 | Wells Fargo | Upgrade | Overweight | $78← $60 |
| May 20th 2024 | Piper Sandler | Upgrade | Overweight | $80← $60 |
| March 18th 2024 | BTIG Research | Upgrade | Buy | $60 |
| October 20th 2023 | ROTH MKM | Initiation | Buy | $75 |
| September 19th 2023 | Stifel | Upgrade | Buy | $61 |
| March 30th 2023 | Canaccord Genuity | Upgrade | Buy | $67 |
| February 13th 2023 | BofA Securities | Downgrade | Underperform | $63← $83 |
| February 10th 2023 | Wells Fargo | Downgrade | Equal Weight | $67 |
| February 10th 2023 | Truist | Downgrade | Hold | $70← $85 |
Earnings History & Surprises
GMEDBeat Rate
84%
Last 19 quarters
Avg Surprise
+11.5%
EPS vs Estimate
Beats / Misses
16/3
Last 12 quarters
Latest EPS
$1.18
Q4 2025
EPS Surprise History
Q1 24
+1.7%
$0.60vs$0.59
Q2 24
+27.0%
$0.72vs$0.57
Q3 24
+10.3%
$0.75vs$0.68
Q4 24
+28.3%
$0.83vs$0.65
Q1 25
+13.5%
$0.84vs$0.74
Q2 25
-8.6%
$0.68vs$0.74
Q3 25
+13.2%
$0.86vs$0.76
Q4 25
+51.1%
$1.18vs$0.78
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 19, 2026 | $1.05 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.78 | $1.18 | +51.1% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.76 | $0.86 | +13.2% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.74 | $0.68 | -8.6% | ✗ MISS |
Q1 2025 | Feb 20, 2025 | $0.74 | $0.84 | +13.5% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $0.65 | $0.83 | +28.3% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.68 | $0.75 | +10.3% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.57 | $0.72 | +27.0% | ✓ BEAT |
Q1 2024 | Feb 20, 2024 | $0.59 | $0.60 | +1.7% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $0.54 | $0.57 | +5.6% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $0.59 | $0.63 | +6.8% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.51 | $0.53 | +3.9% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $0.56 | $0.59 | +5.4% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.52 | $0.50 | -3.8% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $0.53 | $0.56 | +5.7% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $0.47 | $0.42 | -10.6% | ✗ MISS |
Q1 2022 | Feb 17, 2022 | $0.48 | $0.49 | +2.1% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $0.45 | $0.50 | +11.1% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $0.45 | $0.56 | +24.4% | ✓ BEAT |
Q2 2021 | May 4, 2021 | $0.37 | $0.49 | +32.4% | ✓ BEAT |
Latest News
Canaccord Genuity Maintains Buy on Globus Medical, Raises Price Target to $105
📈 PositiveBenzinga•Dec 17, 2025, 07:51 PM•Also:
RBC Capital Maintains Outperform on Globus Medical, Raises Price Target to $100
📈 PositiveBenzinga•Dec 17, 2025, 01:15 PM
Freedom Capital Markets Initiates Coverage On Globus Medical with Hold Rating, Announces Price Target of $87
➖ NeutralBenzinga•Dec 17, 2025, 01:13 PM
Morgan Stanley Maintains Overweight on Globus Medical, Raises Price Target to $100
📈 PositiveBenzinga•Dec 2, 2025, 05:38 PM
Truist Securities Reiterates Buy on Globus Medical, Raises Price Target to $105
📈 PositiveBenzinga•Nov 18, 2025, 01:36 PM
Barclays Maintains Overweight on Globus Medical, Raises Price Target to $114
📈 PositiveBenzinga•Nov 10, 2025, 06:47 PM•Also:
RBC Capital Maintains Outperform on Globus Medical, Raises Price Target to $92
📈 PositiveBenzinga•Nov 7, 2025, 07:06 PM
Wells Fargo Maintains Overweight on Globus Medical, Raises Price Target to $79
📈 PositiveBenzinga•Nov 7, 2025, 06:52 PM
Globus Medical climbs after Q3 beat; Truist upgrades on EPS outlook
📈 PositiveSeeking Alpha•Nov 7, 2025, 03:28 PM
Market-Moving News for November 7th
➖ NeutralBenzinga•Nov 7, 2025, 12:23 PM•Also: ,
Globus Medical shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 guidance.
📈 PositiveBenzinga•Nov 7, 2025, 12:16 PM
B of A Securities Upgrades Globus Medical to Buy, Raises Price Target to $91
📈 PositiveBenzinga•Nov 7, 2025, 11:04 AM
Truist Securities Upgrades Globus Medical to Buy, Raises Price Target to $93
📈 PositiveBenzinga•Nov 7, 2025, 10:44 AM
Globus Medical shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 guidance.
📈 PositiveBenzinga•Nov 6, 2025, 10:16 PM
Globus Medical Raises FY2025 Adj EPS Guidance from $3.00-$3.30 to $3.75-$3.85 vs $3.21 Est; Raises FY2025 Sales Guidance from $2.800B-$2.900B to $2.860B-$2.900B vs $2.855B Est
📈 PositiveBenzinga•Nov 6, 2025, 09:48 PM
Globus Medical Q3 Adj. EPS $1.18 Beats $0.78 Estimate, Sales $769.048M Beat $734.347M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:46 PM
Stifel Reinstates Hold on Globus Medical, Announces $64 Price Target
➖ NeutralBenzinga•Oct 28, 2025, 01:46 PM•Also:
Globus Medical Announces Delaware Jury Returned Verdict In Favor Of Co. In Patent Infringement Against Life Spine
📈 PositiveBenzinga•Aug 28, 2025, 08:31 PM
Globus closes down 23% as earnings misses, lowered EPS guidance weigh
📉 NegativeSeeking Alpha•May 9, 2025, 09:31 PM
Frequently Asked Questions about GMED
What is GMED's current stock price?
Globus Medical, Inc. (GMED) is currently trading at $87.06 per share. The stock has moved +0.21% today.
What is the analyst price target for GMED?
The average analyst price target for GMED is $89.25, based on 1 analyst.
What sector is Globus Medical, Inc. in?
Globus Medical, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NYSE exchange.
What is GMED's market cap?
Globus Medical, Inc. has a market capitalization of $11.65 billion, making it a large-cap company.
Does GMED pay dividends?
No, Globus Medical, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGN
Align Technology, Inc.
$157.69
Mkt Cap: $11.3B
ATR
AptarGroup, Inc.
$121.39
Mkt Cap: $8.0B
BIO
Bio-Rad Laboratories, Inc.
$301.53
Mkt Cap: $8.1B
DVA
DaVita Inc.
$115.20
Mkt Cap: $8.1B
GRFS
Grifols, S.A.
$9.02
Mkt Cap: $7.6B
HQY
HealthEquity, Inc.
$95.50
Mkt Cap: $8.3B
HSIC
Henry Schein, Inc.
$77.35
Mkt Cap: $9.5B
MOH
Molina Healthcare, Inc.
$163.69
Mkt Cap: $8.9B
PEN
Penumbra, Inc.
$315.90
Mkt Cap: $12.4B
Explore stocks similar to GMED for comparison